M. von Mehren

发表

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Soft Tissue Sarcoma, Version 1.2021 Featured Updates to the NCCN Guidelines

M. Heslin, R. Gonzalez, M. Bui, 2022 .

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

K. Owzar, M. Bertagnolli, J. Fletcher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Soft tissue sarcoma.

G. Demetri, M. Heslin, M. Bui, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

A. D. Van den Abbeele, S. Silverman, D. Tuveson, 2002, The New England journal of medicine.

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.

G. Demetri, M. von Mehren, J. Hamm, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Monoclonal antibody-based therapy.

L. Weiner, M. von Mehren, 1996, Current opinion in oncology.

Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

G. Demetri, R. Maki, M. von Mehren, 2019, Cancer.

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

M. von Mehren, M. Mehren, E. Bayever, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma

J. Blay, M. von Mehren, A. Le Cesne, 2008, Clinical Cancer Research.

Role of new chemotherapy agents in soft tissue sarcoma.

M. von Mehren, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

A. Tolcher, M. von Mehren, T. Mays, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Succinate Dehydrogenase Deficiency in Pediatric and Adult Gastrointestinal Stromal Tumors

M. von Mehren, L. Rink, M. Belinsky, 2013, Front. Oncol..

Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study

M. Huang, M. von Mehren, L. Rink, 2014, World Journal of Surgical Oncology.

Soft tissue sarcoma clinical practice guidelines in oncology.

D. Ettinger, G. Demetri, M. Heslin, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

K. Venkatakrishnan, T. Stinchcombe, M. von Mehren, 2012, Clinical Cancer Research.

Other targetable sarcomas.

David M. Thomas, M. van de Rijn, R. Maki, 2009, Seminars in oncology.

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor

Yan Zhou, A. Godwin, M. von Mehren, 2013, PloS one.

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

T. Pajak, A. Godwin, B. Eisenberg, 2009, Molecular Cancer Therapeutics.

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

D. Wechsler, Dorothy Shead, R. Goldsby, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Soft tissue sarcoma of the extremity: Characterizing symptom duration and outcomes.

M. von Mehren, Huaqing Zhao, A. Moten, 2019, Surgical oncology.

Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.

G. Demetri, W. Tap, Q. Wang, 2012, American journal of hypertension.

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

M. McCarter, M. Heslin, R. Gonzalez, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

M. McCarter, M. Heslin, R. Gonzalez, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Robin L. Jones, B. Monk, G. Demetri, 2017, Gynecologic oncology.

Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

J. Goldblum, G. Demetri, M. von Mehren, 2012, Cancer.

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

M. von Mehren, D. Camidge, L. Chow, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis

M. Oberley, M. von Mehren, A. Rosenberg, 2020, Cancers.

Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin

Robin L. Jones, G. Demetri, R. Maki, 2019, Cancer.

A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.

C. Blanke, M. von Mehren, P. Pisters, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Peripheral primitive neuroectodermal tumor of the dura in a 51-year-old woman following intensive treatment for breast cancer

M. von Mehren, L. Goldstein, A. Mukherjee, 2014, The American journal of case reports.

Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines

M. Ross, J. Kirkwood, C. Slingluff, 2010, Journal of immunotherapy.

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas

M. von Mehren, S. Balcerzak, A. Kraft, 2004, Sarcoma.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Nilotinib: a novel, selective tyrosine kinase inhibitor.

J. Blay, M. von Mehren, 2011, Seminars in oncology.

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Robin L. Jones, J. Blay, K. Götze, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy

O. Mir, W. Tap, P. Rutkowski, 2021, The oncologist.

Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, J. Manola, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma

S. Litwin, M. von Mehren, S. Schuetze, 2022, Cancer.

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

M. von Mehren, Z. Wainberg, C. Britten, 2014, Investigational New Drugs.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Robin L. Jones, G. Demetri, H. Tawbi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

J. Sicklick, M. Bui, R. Riedel, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

C. Antonescu, M. McCarter, G. Demetri, 2012, Journal of the American College of Surgeons.

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

J. Hodgson, J. Fletcher, J. Pritchard, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Retroperitoneal Sarcomas: Does Laterality Matter?

M. von Mehren, A. Moten, J. Farma, 2019, The Journal of surgical research.

New therapeutics for soft-tissue sarcomas in adults.

M. von Mehren, 2007, Oncology.

Adolescent and young adult oncology, version 2.2014.

D. Wechsler, Dorothy Shead, R. Goldsby, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans

E. Hostetler, M. von Mehren, R. Alpaugh, 2012, The Journal of Nuclear Medicine.

An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma.

M. von Mehren, R. Benjamin, A. Evens, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.

J. Fletcher, G. Demetri, W. Tap, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments.

Robin L. Jones, Andrea Hayes, J. Blay, 2022, Cancer treatment reviews.

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.

A. D. Van den Abbeele, G. Demetri, B. Eisenberg, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021.

J. Sicklick, S. Dry, M. McCarter, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

Suzanne F. Jones, M. von Mehren, H. Burris, 2009, Clinical Cancer Research.

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Robin L. Jones, J. Blay, M. Heinrich, 2022, BMC cancer.

Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors.

M. Einarson, M. von Mehren, G. Hudes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

E. Plimack, S. Litwin, M. von Mehren, 2014, The oncologist.

Challenges in the treatment of angiosarcoma: a single institution experience.

J. Gaughan, M. von Mehren, J. C. Watson, 2014, American journal of surgery.

Soft Tissue Sarcoma

D. Ettinger, G. Demetri, M. Heslin, 1999 .

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.

M. von Mehren, R. Benjamin, M. Mehren, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

G. Demetri, H. Joensuu, M. Heinrich, 2004 .

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Arijit Chakravarty, Hua Liu, Karthik Venkatakrishnan, 2011, Cancer research.

Gastrointestinal Stromal Tumors.

H. Joensuu, M. von Mehren, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations.

J. Sicklick, O. Harismendy, R. DeMatteo, 2017, JCO precision oncology.

Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case

Stephen J. Capuzzi, J. Chien, A. Godwin, 2015, BMC Cancer.

Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.

A. Godwin, B. Eisenberg, M. von Mehren, 2006, Cancer research.

Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling

Adrian A Canutescu, Wei Shen, Andrew K Godwin, 2005, Clinical Cancer Research.

Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor

Yan Zhou, K. Devarajan, A. Godwin, 2016, Clinical Cancer Research.

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

J. Blay, G. Demetri, M. von Mehren, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal stromal tumours

J. Blay, Yoon-Koo Kang, M. von Mehren, 2009 .

Advances and Challenges on Management of Gastrointestinal Stromal Tumors

M. von Mehren, S. Boikos, M. Idowu, 2018, Front. Oncol..

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Robin L. Jones, J. Blay, M. Heinrich, 2020, The Lancet. Oncology.

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

P. Engstrom, S. Litwin, M. von Mehren, 2011, Cancer Chemotherapy and Pharmacology.

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

J. Blay, G. Demetri, H. Borghaei, 2009, Clinical Cancer Research.

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

C. Antonescu, J. Desai, J. Fletcher, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms.

J. Testa, S. Litwin, M. von Mehren, 2007, Cancer research.

Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide.

J. Blay, G. Demetri, M. von Mehren, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene

G. Castellani, G. Brandi, M. Fiorentino, 2018, International journal of molecular sciences.

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

G. Demetri, A. Racine, H. Joensuu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxorubicin Resistance in a Novel In vitro Model of Human Pleomorphic Liposarcoma Associated with Alternative Lengthening of Telomeres

S. Gagos, M. von Mehren, D. Lev, 2010, Molecular Cancer Therapeutics.

Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas

A. Patchefsky, M. von Mehren, R. Varkonyi, 2005, Clinical Cancer Research.

Telomerase Suppresses Formation of ALT-Associated Single-Stranded Telomeric C-Circles

A. Lazar, M. von Mehren, M. Plantinga, 2013, Molecular Cancer Research.

Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms

M. von Mehren, D. Broccoli, D. Kipling, 2011, Oncogene.

Efficacy of trabectedin for the treatment of liposarcoma

M. von Mehren, Ritika Zijoo, 2016, Expert opinion on pharmacotherapy.

Differential Expression of Cysteine Dioxygenase 1 in Complex Karyotype Liposarcomas

A. Lazar, M. von Mehren, M. Plantinga, 2014, Biomarkers in cancer.

New drugs and combinations for the treatment of soft-tissue sarcoma: a review

M. von Mehren, N. Somaiah, Margaret von Mehren, 2012, Cancer management and research.

High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors

A. Godwin, J. Testa, B. Eisenberg, 2009, Genes, chromosomes & cancer.

Management of Gastrointestinal Stromal Tumors.

M. von Mehren, 2016, The Surgical clinics of North America.

New therapeutic strategies for soft tissue sarcomas.

M. von Mehren, 2003, Current treatment options in oncology.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

Qian Wang, A. D. Van den Abbeele, Edwin Choy, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx).

A. D. Van den Abbeele, J. Manola, G. Demetri, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets

S. Millis, M. von Mehren, B. V. Van Tine, 2015, Oncotarget.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

G. Demetri, B. Eisenberg, M. Heinrich, 2009, Journal of surgical oncology.

Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?

M. von Mehren, Katya Ahr, Jordan J. Senchak, 2022, Current Treatment Options in Oncology.

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

P. Meltzer, J. Schiffman, C. Stratakis, 2016, JAMA oncology.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

J. Crowley, G. Demetri, R. Maki, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adolescent and young adult oncology. Clinical practice guidelines in oncology.

D. Wechsler, Dorothy Shead, R. Goldsby, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

G. Adams, M. von Mehren, M. Mehren, 2008, British Journal of Cancer.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

J. Fletcher, G. Demetri, H. Joensuu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors

J. Blay, M. von Mehren, M. Blackstein, 2010, Cancer.

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

J. Schlom, H. Cooper, L. Weiner, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Recent advances in immunotherapy and monoclonal antibody treatment of cancer.

G. Adams, L. Weiner, M. von Mehren, 2000, Seminars in oncology nursing.

Monoclonal antibody therapy for cancer.

G. Adams, L. Weiner, M. von Mehren, 2003, Annual review of medicine.

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

A. D. Van den Abbeele, J. Blay, D. Ettinger, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

C. Antonescu, G. Demetri, C. Raut, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors

A. Godwin, B. Eisenberg, M. von Mehren, 2008, Cell cycle.

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study

Robin L. Jones, O. Mir, W. Tap, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor

M. Heinrich, M. von Mehren, S. George, 2021, Frontiers in Oncology.

Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor

K. Devarajan, S. Litwin, M. von Mehren, 2021, bioRxiv.

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

Robin L. Jones, O. Mir, W. Tap, 2021, European journal of cancer.

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

Robin L. Jones, O. Rosen, M. Heinrich, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.

Robin L. Jones, O. Mir, W. Tap, 2020, The Lancet. Oncology.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib

Dafydd G. Thomas, V. Bolejack, D. Reinke, 2018, JAMA oncology.

Emerging drugs for the treatment of gastrointestinal stromal tumour

M. von Mehren, Vineela Kasireddy, 2017, Expert opinion on emerging drugs.

GIST Treatment Options after Tyrosine Kinase Inhibitors

M. von Mehren, Natthapol Songdej, 2014, Current Treatment Options in Oncology.

Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging

James R. Johnson, K. Devarajan, A. Godwin, 2013, Cancer biology & therapy.

Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.

M. von Mehren, J. Vadakara, Joseph Vadakara, 2013, Hematology/oncology clinics of North America.

An unusual site of metastasis from gastrointestinal stromal tumor

M. von Mehren, J. Trent, J. Yu, 2010, Rare tumors.

New therapeutic approaches for advanced gastrointestinal stromal tumors.

M. von Mehren, N. Somaiah, 2009, Hematology/oncology clinics of North America.

Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?

M. von Mehren, J. C. Watson, 2009, Oncology.

Gastrointestinal stromal tumors.

M. von Mehren, J. C. Watson, 2005, Hematology/oncology clinics of North America.

Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial

C. Antonescu, M. McCarter, K. Owzar, 2013, Annals of surgery.

Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1

R. Maki, R. Riedel, M. von Mehren, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

G. Hoehn, M. Heinrich, M. von Mehren, 2021, BMC Cancer.

Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group

C. Raut, P. Rutkowski, M. von Mehren, 2020, Cancer.

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

A. D. Van den Abbeele, J. Crowley, D. Flieder, 2019, Clinical Cancer Research.

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST

Yan Zhou, M. von Mehren, L. Rink, 2017, BMC Cancer.

Gastrointestinal Stromal Tumors: A Paradigm for Molecularly Targeted Therapy

M. von Mehren, 2003, Cancer investigation.

Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future

M. von Mehren, A. Mackenzie, 2007, Expert review of anticancer therapy.

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

Nicolas Widmer, M. von Mehren, Nicolas Widmer, 2011, Cancer treatment reviews.

SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma

Dafydd G. Thomas, J. Wathen, H. Tawbi, 2016, Cancer.

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment

James S. Duncan, Yan Zhou, M. Einarson, 2020, JCI insight.

Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal Tumor

James S. Duncan, Yan Zhou, M. Einarson, 2020, bioRxiv.

Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

David M. Thomas, Kevin B. Jones, Robin L. Jones, 2021, Cancer.

Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic.

J. Schiffman, C. Stratakis, C. Weldon, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

Robin L. Jones, J. Blay, M. Heinrich, 2021, The oncologist.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033

J. Crowley, K. Owzar, J. Fletcher, 2017, JAMA oncology.

A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

M. von Mehren, S. Schuetze, M. Mehren, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deciding on the duration of adjuvant therapy in gastrointestinal stromal tumor

M. von Mehren, Erika Correa, P. Whooley, 2020, Expert review of anticancer therapy.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

C. Antonescu, M. McCarter, K. Owzar, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors

M. von Mehren, 2008, Current opinion in oncology.

Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.

Andrew K Godwin, Jonathan Fletcher, J. Fletcher, 2003, Molecular cancer therapeutics.

Pharmacotherapy of gastrointestinal stromal tumours

B. Eisenberg, M. von Mehren, 2003, Expert opinion on pharmacotherapy.

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

G. Demetri, H. Joensuu, M. Heinrich, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dataset for reporting of gastrointestinal stromal tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR)

E. Wardelmann, C. Raut, A. D. Dei Tos, 2022, Histopathology.

SMARCA2‐NR4A3 is a novel fusion gene of extraskeletal myxoid chondrosarcoma identified by RNA next‐generation sequencing

A. Patchefsky, H. Cooper, M. von Mehren, 2021, Genes, chromosomes & cancer.

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

D. Flieder, A. Godwin, J. Testa, 2008, Proceedings of the National Academy of Sciences.

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

G. Demetri, Tanmay Parekh, R. Maki, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Patterns of Chemotherapy Administration in High-Risk Soft Tissue Sarcoma and Impact on Overall Survival.

M. von Mehren, E. Ross, S. Movva, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

I Judson, J Verweij, J. Blay, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Granular cell tumor experience at a comprehensive cancer center.

Hong Wu, M. von Mehren, A. Moten, 2018, Journal of Surgical Research.

Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.

J. Schlom, H. Cooper, L. Weiner, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.

M. Ross, C. Slingluff, W. Grosh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Head and Neck Sarcomas: A Comprehensive Cancer Center Experience

M. von Mehren, M. Tejani, J. Ridge, 2013, Cancers.

Soft tissue sarcoma, version 2.2014.

John D Pfeifer, Marilyn M Bui, Herbert S Schwartz, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

A. Benson, H. Lenz, J. Marshall, 2008, Clinical Cancer Research.

Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins

L. Weiner, M. von Mehren, R. Alpaugh, 1997, Cancer Immunology, Immunotherapy.

A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.

A. Godwin, H. Joensuu, A. Lazar, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.

Robin L. Jones, M. Heinrich, M. von Mehren, 2021, European journal of cancer.

New therapies in soft tissue and bone sarcomas.

M. von Mehren, 2011, Clinical advances in hematology & oncology : H&O.

Treatment Patterns and Distance to Treatment Facility for Soft Tissue Sarcoma of the Extremity.

M. von Mehren, E. Handorf, A. Moten, 2020, The Journal of surgical research.

Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older

Alexandra L Hanlon, Kathryn Evers, Nicos Nicolaou, 2003, Cancer.

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas.

M. von Mehren, M. Mehren, S. Balcerzak, 2004, Sarcoma.

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.

E. Plimack, B. Egleston, M. von Mehren, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies

M. von Mehren, J. Farma, S. Greco, 2021, Annals of Surgical Oncology.

Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.

E. Plimack, B. Egleston, M. von Mehren, 2016, Journal of oncology practice.

Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.

J. Blay, H. Joensuu, R. Maki, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD).

M. von Mehren, A. Yver, R. Cohen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.

W. Tap, P. Rutkowski, M. von Mehren, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

G. Hoehn, M. Heinrich, M. von Mehren, 2021, BMC cancer.

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

G. Demetri, R. Riedel, M. Heinrich, 2016, European journal of cancer.

Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens.

O. Rosen, M. Heinrich, M. von Mehren, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage

M. von Mehren, Dhara Patel, S. Movva, 2019, Sarcoma.

Gastrointestinal stromal tumors, version 2.2014.

John D Pfeifer, Marilyn M Bui, Herbert S Schwartz, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis.

Andrew K Godwin, Bhavinkumar B. Patel, A. Godwin, 2008, Cancer genomics & proteomics.

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Robin L. Jones, J. Blay, M. Heinrich, 2021, Clinical Cancer Research.

INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2022, Journal of Clinical Oncology.

Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033.

J. Crowley, G. Demetri, C. Blanke, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin--a targeted chemotherapy?

M. von Mehren, 2007, The Lancet. Oncology.

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

D. Ettinger, R. Carlson, A. Benson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST

Yan Zhou, M. von Mehren, L. Rink, 2017, BMC Cancer.

Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, G. Demetri, W. Hayes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Trials in the Age of Pandemics.

M. Edelman, M. von Mehren, E. Ross, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Targeted therapy with imatinib: hits and misses?

M. von Mehren, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety profile of therapeutic pox virus-based vaccines for cancer.

R. DiPaola, J. Marshall, J. Schlom, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.

D. Ettinger, R. Carlson, A. Benson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment

J. Gralow, L. Weiner, M. von Mehren, 1997, Cancer Immunology, Immunotherapy.

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

A. D. Van den Abbeele, J. Manola, J. Fletcher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone Cancer.

Robin L. Jones, B. Brigman, F. Frassica, 2007, American family physician.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

J. Blay, S. Rodenhuis, G. Demetri, 2013 .

Ripretinib for advanced gastrointestinal stromal tumours - Authors' reply.

J. Blay, M. von Mehren, 2020, The Lancet. Oncology.

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.

J. Sicklick, M. Bui, R. Riedel, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor

A. Godwin, M. von Mehren, Yan Ma, 2014, Molecular Cancer Therapeutics.

Gastrointestinal stromal tumours

J. Blay, Yoon-Koo Kang, M. von Mehren, 2021, Nature Reviews Disease Primers.

Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Douglas C. Fair, C. Pratilas, M. von Mehren, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2023, Journal of Clinical Oncology.

Bone cancer.

Robin L. Jones, B. Brigman, F. Frassica, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Colorectal cancer vaccines: what we know and what we don't yet know.

M. von Mehren, M. Mehren, 2005, Seminars in oncology.

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

Robin L. Jones, B. Monk, G. Demetri, 2021, Cancer medicine.

Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines

John D. Pfeifer, Richard J. O'Donnell, Robert S. Benjamin, 2014 .

Pan-sarcoma analysis of DNA damage response pathway alterations and deficiency.

M. von Mehren, J. Trent, G. D'Amato, 2022, Journal of Clinical Oncology.

A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).

J. Blay, G. Demetri, M. von Mehren, 2006, Journal of Clinical Oncology.

Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

M. von Mehren, 2006, Clinical colorectal cancer.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

A. D. Van den Abbeele, J. Manola, J. Fletcher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

C. Stratakis, M. von Mehren, S. George, 2016, JAMA oncology.

Patterns of Chemotherapy Administration in High-Risk Soft Tissue Sarcoma and Impact on Overall Survival.

M. von Mehren, E. Ross, S. Movva, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Gastrointestinal Stromal Tumors.

H. Joensuu, M. von Mehren, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. von Mehren, Nicolas Widmer, 2011, Cancer treatment reviews.

Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.

M. von Mehren, Joseph Vadakara, 2013, Hematology/oncology clinics of North America.

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

G. Demetri, H. Joensuu, M. Heinrich, 2004, Blood.

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

M. von Mehren, H. Gelderblom, P. Schöffski, 2024, Nature medicine.

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape

J. Sicklick, M. von Mehren, Isabella Klooster, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma.

M. von Mehren, S. Okuno, M. Agulnik, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.